W

ASHINGTON — The pharmaceutical industry’s massive lobbying operation has a well-earned reputation for maintaining a united front on most of the major policy proposals that could affect drug makers and their bottom lines. But as the industry eyes the burgeoning biosimilar market, that united front is starting to crack.

For years, branded pharmaceutical and biotech manufacturers — largely represented by PhRMA and BIO — have clashed most often with generic manufacturers, largely represented by their own Association for Accessible Medicines.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy